Along the same line, adding erlotinib to chemoradiation and bevacizumab did not show efficacy but induced esophageal toxicity in NSCLC (140) and the addition of the EGFR/VEGFR inhibitor vandetanib did not prolong survival in a phase II study of glioblastoma (141). This evidence concerns the gene EGFR and glioblastoma.